Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05308849
Other study ID # 2021-A00378-33
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 31, 2022
Est. completion date June 30, 2024

Study information

Verified date March 2022
Source Central Hospital, Nancy, France
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilote monocentric prospective study about pediatric peritonitis and antibiotics pharmacokinetic and pharmacodynamic. The investigators will include 41 patients between 3 and 17 years-old during 2 years in the University Hospital of Nancy. The aim of this study is to determine if the beta-lactam dosages in children recommended by the guidelines for management of intra-abdominal infections permitted the achievement of adequatly serum and peritoneal concentrations in the medical and surgical management of peritonitis. The investigators will collected serum and peritoneal fluid samples at 3 different times: peritoneal incision, end of surgery, 2 days and 5 days after surgery in order to compare the concentrations and the minimal inhibitor concentration of bacteria. The hypothesis is that of a serum and peritoneal antibiotic under dosage.


Description:

Pediatric population with localized or generalized appendicular peritonitis with surgical management at the Nancy University Hospital. Patients are usually taken in emergency at the Pediatric Emergency Department (Children's Hospital, CHRU Nancy). The diagnosis of peritonitis is then made or confirmed by clinical examination and paraclinical tests (biology and imaging). Written informed consent is obtained from one of the parental authority holders, allowing inclusion in the study. An information document adapted to the child's understanding will also be sent to him/her. The child's non-opposition will be sought if he/she is old enough to understand. The information will be given jointly to the child and to the legal guardians present at the patient's bed at the time of diagnosis of peritonitis. The reflection period will correspond to the interval between this information and the management in the operating room. This may vary depending on the occupation of the operating room. The diagnosis of appendicular peritonitis is made by the surgeon (routine care). The child is included. Antibiotic therapy is started IV according to the protocol in force at the CHRU (routine care): - Cefotaxime (200 mg/kg/d, 4 IV administrations) + Metronidazole (20-30 mg/kg/d, 3 IV administrations)+/-Gentamicin (3-8 mg/kg/d IV) Specific biological samples and collections are taken for the research: - A blood sample (1mL) (S0) after injection of the antibiotic and before appendicular section, non-invasive because performed on peripheral venous route. - A blood sample (1mL) (S1) at the end of the operation, either when the peripheral venous route is placed if possible (non-invasive), otherwise at the periphery (invasive). - If a drainage of the peritoneal cavity is in place, a non-invasive collection of peritoneal fluid (5 mL) on the drain will be performed (P1) at D2. - If generalized peritonitis, an additional blood collection (1mL) at D5 (S2) during the biological check-up (routine care). If an abdominal drainage is still in place, a non-invasive collection of peritoneal fluid (5mL) on drain will be performed (P2). At D5, the patients are under appropriate antibiotic therapy. Specifically for research, betalactam assays are performed on S0, S1, S2, P0, P1 and P2 once all samples have been sent to Pharmacology. Bacteriological analyses are performed on P0 (routine care), P1 and P2 in real time. The following specific data will be collected: time of first antibiotic administration, time of sampling (S0, S1 and P0), time of surgery start. Data concerning antibiotic therapy (dosage, frequency of administration) will be collected during the entire hospitalization period as well as the time of the other samples if applicable (S2, P1 and P2). Clinical and biological data are collected, including the visit at 4-6 weeks after discharge. (In routine care, a visit at 1 month post-op is performed). The investigator looks for AEs or SAEs. At the end of this post-operative visit, the patient is discharged from the study. The volume of blood collected in the framework of the research is estimated at 3mL, i.e. less than 2.5% of the total blood volume over the inclusion period. The maximum total volume collected is 24 mL (6 mL for research, 18 mL for care, i.e. 3 samples of CBC, blood ionogram and CRP). Blood and peritoneal samples : The 3 blood samples as well as the 2 (possibly 3) peritoneal samples will be taken by a nurse and will be placed in a specific bag. Each sampling time will be clearly identified on the sample and a traceability form will be completed and sent to the Pharmacology and Toxicology laboratory.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 41
Est. completion date June 30, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 17 Years
Eligibility Inclusion Criteria: - diagnosis of intra-abdominal infection : localized or generalized peritonitis secondary to appendix Exclusion Criteria: - betalactams allergy - peritonitis with other etiology than appendix - antibiotic treatment longer than 24h

Study Design


Intervention

Other:
Dosage of serum and peritoneal of the betalactam used for antibiotic treatment
All patients will have antibiotherapy according to French recommendation. Antibiotics recommended are: cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d Blood samples will be collected before surgery and after surgery (for all patients). Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5. Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Central Hospital, Nancy, France PAPE Elise

Outcome

Type Measure Description Time frame Safety issue
Primary antibiotic concentration Serum betalactams concentrations at different times Peritoneal incision, end of surgery, Day+5 after surgery if systemic peritonitis,
Primary antibiotic concentration Peritonal betalactams concentrations at different times During surgery, Day+2 after surgery if drain peritonal, Day+5 after surgery if systemic peritonitis,
Secondary Determine elimination rate constant Kel It is the first order rate constant describing drug elimination from the body. Statistical analysis after 2 years of inclusion
Secondary Determine estimated initial concentrationf C0 Initial concentration of antibiotic in the body Statistical analysis after 2 years of inclusion
Secondary Determine Area Under the Curve AUC. It is the definite integral of a curve that describes the variation of a drug concentration in blood plasma as a function of time. Statistical analysis after 2 years of inclusion
Secondary Determine Half-life It is a pharmacokinetic parameter that is defined as the time it takes for the concentration of the drug in the plasma or the total amount in the body to be reduced by 50%. Statistical analysis after 2 years of inclusion
Secondary Determine distribution volume It is a pharmacokinetic parameter representing an individual drug's propensity to either remain in the plasma or redistribute to other tissue compartments. Statistical analysis after 2 years of inclusion
Secondary Determine Clearance or betalactams in children It is a pharmacokinetic measurement of the volume of plasma from which a substance is completely removed per unit time. Statistical analysis after 2 years of inclusion
Secondary Evaluate the relationship between serum and peritoneal concentrations of beta-lactam Determination of the antibiotic diffusion coefficient through the peritoneal membrane : difference between serum concentration and peritoneal concentration of betalactam Statistical analysis after 2 years of inclusion
Secondary Proportion of different bacteria Describe the local bacterial ecology Statistical analysis after 2 years of inclusion
Secondary Proportion of sensitive and resistant germs to betalactam antibiotics Describe the local bacterial ecology Statistical analysis after 2 years of inclusion
Secondary Description of minimal inhibition concentration for bacterias Describe the local bacterial ecology Statistical analysis after 2 years of inclusion
Secondary Factors associated with an antibiotic under-dosage Factors statistically associated with antibiotic under dosage defined by serum and peritonal concentrations < 4*MIC using multivariate analysis. Statistical analysis after 2 years of inclusion
Secondary Factors associated with an antibiotic overdose Factors statistically associated with antibiotic overdose defined by serum and peritonal concentrations >10*MIC using multivariate analysis. Statistical analysis after 2 years of inclusion
Secondary Evaluation of duration of hospitalization Describe the clinical efficacy of antibiotic protocol Statistical analysis after 2 years of inclusion
Secondary Mean delay for apyrexia Describe the clinical efficacy of antibiotic protocol Statistical analysis after 2 years of inclusion
Secondary Clinical complications Describe the clinical efficacy of antibiotic protocol Statistical analysis after 2 years of inclusion
See also
  Status Clinical Trial Phase
Completed NCT04529980 - Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis N/A
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Recruiting NCT03522233 - Pediatric Appendicitis Risk Calculator (pARC) in Children With Appendix Ultrasounds
Recruiting NCT03380793 - A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis Phase 4
Recruiting NCT02108340 - Comparative Study of Microwave Radiometry and Ultrasonography for the Diagnosis of Acute Appendicitis N/A
Terminated NCT02029781 - The Laparoscopic Appendicitis Score; a Multicenter Validation Study N/A
Completed NCT01356641 - Antibiotic Treatment Alone for Acute Simple Appendicitis in Children N/A
Completed NCT01515293 - Single Incision Versus Conventional Laparoscopic Appendectomy Phase 3
Completed NCT00913380 - Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT Phase 3
Terminated NCT00971438 - Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging N/A
Completed NCT00530998 - Minimally Invasive Surgery: Using Natural Orfices
Completed NCT00616616 - Single Incision Laparoscopy N/A
Completed NCT00195351 - Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection Phase 4
Completed NCT02916134 - Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis N/A
Completed NCT04614649 - Right Iliac Fossa Treatment-Turkey Audit
Completed NCT04365491 - European Society for Trauma and Emergency Surgery (ESTES) Cohort Study Snapshot Audit 2020 - Acute Appendicitis
Completed NCT03770897 - Laparoscopic Appendectomy Performed by Junior SUrgeonS: Impact of 3D Visualization on Surgical Outcome N/A
Completed NCT02507674 - Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study
Active, not recruiting NCT01718275 - Non-operative Management of Early Appendicitis in Children
Terminated NCT01575028 - Transversus Abdominis Plane (TAP) Versus Local Anesthetic for Lap Appendectomies Phase 2